

Nutrition/Interventional - ICELAND

Competent authority

Contact Details

Contact Name 1

Icelandic Medicines Agency (IMA)

Phone

520 2100

Fax

561 2170

Email Department

clinical.trials@ima.is

Address

Vínlandsleið 14

ZIP/City

113 Reykjavík

Country

Iceland (IS)

Web address

<http://www.ima.is>

Additional Information

No local CA

Trial Authorisation / Registration / Notification

Regulatory and ethics bodies involved in approval process

National Ethics Committee
Agency for data protection

Regulatory and ethics bodies involved in approval process for trials including patients

Institutional Ethics Committee

Regulatory and ethics bodies involved in approval process for trials including including healthy participants

—

Regulatory and ethics bodies involved in approval process for trials including vulnerable population

—

CA - Registration/ notification without approval required for

—

CA - Registration requirements for clinical trials

Registration recommended
Not mandatory

Registration requirements for clinical trials including patients

—

| | |
|-------------------------|---|
| | Registration requirements for clinical trials including healthy participants — |
| | Registration requirements for clinical trials including vulnerable population — |
| | Registration requirements - Additional information The registration is not mandatory according to our regulations, but we register all nutrition intervention trials, both in healthy people and patients |
| | CA - Submission required to — |
| | Studies including patients - submission required to Institutional CA |
| | Studies including healthy participants - submission required to — |
| Submission Format | Studies including vulnerable population - submission required to — |
| | Standard application form available No |
| Language of Submission | Additional Information Only in pharmaceuticals |
| | Language(s) of application Icelandic |
| | Language(s) of application for trials including patients — |
| | Language(s) of application for trials including healthy participants — |
| | Language(s) of application for trials including vulnerable population — |
| | Preferred language of application — |
| | English accepted Partly, not for all documents |
| | Documents mandatory to be in official national language — |
| | Documents mandatory to be in local language of study site — |
| | Documents mandatory to be in language of the study participant — |
| Timelines Authorisation | Additional Information Time to approval CA 4-8 weeks (average) |

—

Ethics committee

Contact Details

Contact Name 1

The National Bioethics Committee - NBC (Vísindasiðanefnd)

Phone

+354 55171100

Address

Tryggvagata 17

ZIP/City

101 Reykjavík

Country

Iceland (IS)

E-Mail

vsn@vsni.is

Web address

<http://www.vsn.is/en>

Additional Information

Relevant for most of the nutritional studies

Ethical Review – General

Submission for Ethical review mandatory for

—

Submission of study mandatory

Yes

Submission to CA and EC to be performed in the following order

—

National declaration on Ethical requirements exists

Yes

Single-Centre Studies - Ethical Review

Ethical approval (favourable opinion) to be obtained from

International EC

National EC

Ethical approval (favourable opinion) for trials including patients to be obtained from

Institutional EC

Ethical approval (favourable opinion) for trials including healthy participants to be obtained from

—

Ethical approval (favourable opinion) for trials including vulnerable population to be obtained from

—

Multi-Centre Studies - Ethical Review

Ethical approval (favourable opinion) required from

Single Opinion

| | |
|---------------------------|---|
| | <p>Ethical approval in trials including patients obtained from</p> <p>—</p> <p>Ethical approval in trials including healthy participants obtained from</p> <p>—</p> <p>Ethical approval in trials including vulnerable population obtained from</p> <p>—</p> |
| Submission of Application | <p>Entitled to study submission</p> <p>Uncertain</p> <p>Entitled to submission of trials including patients</p> <p>—</p> <p>Entitled to submission of trials including healthy participants</p> <p>—</p> <p>Responsible for submission of trials including vulnerable population</p> <p>—</p> <p>Prerequisites for submission / approval</p> <p>—</p> |
| Submission Format | <p>Standard application form available</p> <p>Yes</p> <p>Standard application form</p> <p>Standard application form</p> |
| Language of Submission | <p>Language(s) of application</p> <p>Icelandic</p> <p>Language(s) of application for trials including patients</p> <p>—</p> <p>Language(s) of application for trials including healthy participants</p> <p>—</p> <p>Language(s) of application for trials including vulnerable population</p> <p>—</p> <p>Preferred language of application</p> <p>—</p> <p>English accepted</p> <p>Partly, not for all documents</p> <p>Documents mandatory to be in official national language</p> <p>—</p> <p>Documents mandatory to be in local language of study site</p> <p>—</p> <p>Documents mandatory to be in language of study participant</p> <p>—</p> |

| | |
|--|--|
| Timelines Ethical Review | Additional Information Time to approval CA 4-8 weeks (average) |
| Safety Reporting | Investigator shall report SAE to Uncertain Investigator shall report SAE in trials with patients to — Investigator shall report SAE in trials with healthy participants to — Investigator shall report SAE in trials with volunteers to — |
| Study specific Requirements | |
| Investigator | Entitled to be principal investigator Not specified Entitled to be principal investigator for trials with patients — Entitled to be principal investigator for trials with healthy participants — Entitled to be principal investigator for trials with vulnerable population — |
| Study Participants - Informed Consent (IC) | Standard IC form (ICF) available No Accepted format of Informed Consent (IC) form Written consent Accepted format of IC form for studies including patients — Accepted format of IC form for studies including healthy participants — Accepted format of IC form for studies including vulnerable population — |
| Study Participants - Vulnerable Population | Considered as vulnerable population Children Elderly Pregnant women (Pregnancy) Lactating women Unconscious Persons Incapacitated adults People with psychiatric disorder People with dementia Prisoners Regulations concerning the inclusion or exclusion available Yes |

| | |
|---|---|
| | Applicable ethical regulations Institutional National International EU directive (2001/20/EC) |
| Study Participants - Compensation & Reimbursement | Reimbursement for study participants Uncertain Reimbursement for patients — Reimbursement for healthy participants — Reimbursement for vulnerable population — Compensation is limited to/provided for Not specified Compensation for patients is limited to/provided for — Compensation for healthy participants is limited to/provided for — Compensation for vulnerable population is limited to/provided for — |
| Funding | Trials generally financially supported by industry Not specified Funding is an issue during the approval process Not specified |
| Study Participants - Recruitment & Trial Outcome | Regulations on recruitment process exist Yes |
| Insurance | Liability insurance or alternative arrangements for damages mandatory for Patients/Volunteers Researchers Obligation to contract a liability insurance for trials including patients for — Obligation to contract a liability insurance for trials including healthy participants for — Obligation to contract a liability insurance for trials including vulnerable population for — Insurance fee in € value indicated as — |

| | |
|---|--|
| | <p>Insurance fee in € value indicated as</p> <p>—</p> |
| Quality Assurance/ Quality Control (QA/QC) | <p>Regularly performed methods</p> <p>Not specified</p> <p>Regularly performed methods in trials including patients</p> <p>—</p> <p>Regularly performed methods in trials including healthy participants</p> <p>—</p> <p>Regularly performed methods in trials including vulnerable population</p> <p>—</p> <p>Regularly performed methods - Additional information</p> <p>Standard Operating Procedures (SOPs) and Case Report Form (CRF) only in pharmaceuticals/drug trials</p> <p>Standards concerning quality assurance and quality control</p> <p>Only in pharmaceuticals/drug trials</p> <p>Regularly performed audits</p> <p>—</p> <p>Regularly performed audits in trials including patients</p> <p>—</p> <p>Regularly performed audits in trials including healthy participants</p> <p>—</p> <p>Regularly performed audits in trials including vulnerable population</p> <p>—</p> <p>Regularly performed audits - Additional information</p> <p>Uncertain</p> |
| Archiving & Data Management | <p>Study documents must be kept at least (in years)</p> <p>—</p> <p>Legal framework for data management exists</p> <p>Yes</p> |

National legislation

| | |
|---|---|
| General Information: Applicable Legislation & Conventions | <p>Applied regulatory conventions</p> <p>Declaration of Helsinki Other ethical principles for medical research (other than Declaration of Helsinki) National regulatory requirements</p> <p>Applied regulatory conventions in studies including patients</p> <p>Institutional regulatory requirements</p> <p>Applied regulatory conventions in studies including healthy participants</p> <p>—</p> |
|---|---|

| | |
|------------------------|--|
| | <p>Applied regulatory conventions in studies including vulnerable population</p> <p>—</p> <p>Applicable national laws</p> <p>—</p> <p>Applicable national laws for patients</p> <p>Hospital Act Data protection Act Medical device act Drug act</p> <p>Applicable national laws for healthy participants</p> <p>Not specified</p> <p>Applicable national laws for vulnerable population</p> <p>—</p> <p>National regulations for volunteers exist for</p> <p>—</p> |
| Nutrition | <p>Nutrition considered as drug</p> <p>No</p> |
| Blood & Tissue Samples | <p>Tissue samples permitted</p> <p>Not specified</p> |
| Data Protection | <p>Specific Requirements</p> <p>Yes</p> <p>Legal framework (on safeguarding the collection, handling, recording, keeping and/or processing of any clinical trial related data and patient files)</p> <p>—</p> |
| Invasive Catheters | <p>Invasive catheters permitted</p> <p>Not specified</p> |
| Definition | |
| Interventional Study | <p>Definition in national law</p> <p>Traditionally the term intervention study is used for clinical trials and randomized trials (for dietary intervention studies meaning changing/providing earlier dietary habits)</p> |